Updates

Get Alerts
With a free MyAccess profile, you can sign up to receive an email alert when new content is published on this site.
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 3) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2016 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2014 New and Noteworthy FDA Approvals Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2013 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2013 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2012 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2012 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2011 New and Noteworthy FDA Approvals (Part 2) Nelda Murri, PharmD, MBA
2/1/2018 9:35:23 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update The Goodman & Gilman Year in Review: 2011 New and Noteworthy FDA Approvals (Part 1) Nelda Murri, PharmD, MBA
12/2/2015 6:00:53 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update Update 62-1 Idelalisib: A First-in-Class Specific Inhibitor of PI3Kδ for the Treatment of B-cell lymphomas (ABSTRACT) Randa Hilal-Dandan, PhD
2/25/2015 2:22:36 PM | Goodman & Gilman's The Pharma. Basis of Therapeutics Updates General Update Programmed Cell Death-1 (PD-1) Pathway Checkpoint Inhibition: Immuno-oncology for Advanced Melanoma David Woessner, PhD, MS